论文部分内容阅读
偏头痛型血管型头痛（简称偏头痛），其发病机理目前尚未完全阐明．临床治疗用药很繁杂，效果均不理想。有的药物（如酒石酸麦角胺）疗效确切，但仅能缓解症状．不能预防再次发作，且副作用大。有的药物，虽有一定疗效，但药源缺乏或价格昂贵，不宜推广使用．我们研制了偏头痛散胶囊，自１９９５年１月开始与酒石酸麦角胺咖啡因片（麦咖片）对照研究。结果显示偏头痛散胶囊在减少头痛发作次数，减轻疼痛程度及总有效率方面与麦咖片大体相同（Ｐ＞０．０５），而在远期预防效果上有显著差异（Ｐ＜０．０１），偏头痛散胶囊明显优于麦咖片．本胶囊副作用很少，药源充足，价格便宜，易于推广使用。
Migraine type vascular headache (referred to as migraine), the pathogenesis has not been fully elucidated. Clinical medication is complicated, the effect is not ideal. Some drugs (such as ergotamine tartrate) curative effect, but only relieve symptoms. Can not prevent another attack, and side effects. Some drugs, although a certain effect, but the lack of drug or expensive, should not be promoted. We have developed a migraine capsule, since January 1995 with ergot caffeine tartrate tablets (wheat coffee tablets) control study. The results showed that migraine powder capsules reduce the number of headache attacks, reduce the degree of pain and the total effective rate is almost the same with the wheat coffee tablets (P> 0.05), while the long-term prevention effect was significantly different (P <0.01 ), Migraine headache capsule was significantly better than wheat coffee tablets. Little side effects of this capsule, adequate source of drugs, cheap, easy to promote the use of.